Generation of dysferlin deficient inducible pluripotent stem cell lines

Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual’s stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI’s facilities are located in Madison, Wisconsin. See

Past Projects

Cellular Dynamics International, Inc. (CDI), a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, will create five induced pluripotent stem cell (iPSC) lines from patients with muscular dystrophies caused by dysferlin protein deficiency. As there are currently no effective treatments for these genetic disorders, establishing model iPSC lines is an important step toward developing new drugs and therapies for these patients.

Project Summary:  CDI will employ their MyCell® Products line to create dysferlinopathy patient-derived iPSC lines. All five of the donors for this project have been recruited.  iPSC technology is based on reprogramming adult cells to a pluripotent stem cell state, whereby the resulting iPSCs, and the somatic cells derived from them, carry the genotypic backgrounds of the original donors and can be used to model their disease. A primary goal of the Jain Foundation is to use these disease models for drug discovery and assessing therapeutic interventions.